Zankiren

This classification denotes an antihypertensive agent with the molecular formula C35H55N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I36B16A34Q, chemically known as 4-thiazolepropanamide, n-((1s,2r,3s)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2s)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (alphas)- but generally known as zankiren, which bears US NIH Compound Identifier 3036088. European Medicines Agency schedules Zankiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00138MIG. The term ZANKIREN is an International Non-Proprietary Name. ZANKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zankiren under HS 29341000 and SITC 51579. As of Q4 2014, ZANKIREN remains the US FDA Preferred Term for this commodity. Zankiren bears US NLM identifiers UMLS ID C2987041 and NCI Concept Code C95290. SMILES: S(=O)(=O)(N1CCN(CC1)C)CC(C(=O)NC(C(=O)NC(CC1CCCCC1)C(O)C(O)CC(C)C)Cc1ncsc1)Cc1ccccc1.